Figure 2 Three-year survival rates on the basis of body composition

Slides:

Advertisements

Similar presentations

Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:

Advertisements

Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 7 Mendelian randomization of overlapping exposures

Nat. Rev. Cardiol. doi: /nrcardio

Figure 10 Assessment of myocardial fibrosis

Figure 2 Different manifestations of myocardial ischaemia

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 5 BMI and cardiorespiratory fitness levels

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 1 Cine cardiovascular magnetic resonance (CMR)

Figure 4 BMI and mortality in patients with heart failure

Mechanism by which negative sodium and water balance may improve myocardial and renal function in CHF. [Reprinted from J Am Coll Cardiol, vol. 47, Schrier.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Size categorization of airborne pollutants

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Physical activity and obesity levels by WHO-designated region and sex Figure 2 | Physical activity and obesity levels by WHO-designated region.

Figure 8 4D magnetic resonance imaging patterns

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 2 Imaging of atherosclerotic plaque burden

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Nat. Rev. Cardiol. doi: /nrcardio

Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the “Obesity Paradox” Carl J. Lavie, MD, Richard V.

Figure 1 Cardiovascular risk and disease across the life-course

Figure 1 Decision tree integrating the assessment,

Figure 4 TAVI for bicuspid aortic valve disease

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

The Obesity Paradox, Weight Loss, and Coronary Disease

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Figure 2 Absolute difference in seasonal peak

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Observational studies on multiple treatment strategies

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Serum phosphate level is associated with

Figure 6 The neurogenic components of angina

Nat. Rev. Cardiol. doi: /nrcardio

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Figure 2 Three-year survival rates on the basis of body composition Figure 2 | Three-year survival rates on the basis of body composition. Mortality was highest in the low body fat (BF)/low lean mass index (LMI) group (15%), followed by the high BF/low LMI group (5.7%), low BF/high LMI group (4.5%), and high BF/high LMI group (2.2%). Reproduced from Lavie, C. J. et al. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the “obesity paradox.” J. Am. Coll. Cardiol. 60, 1374–1380 (2012), with permission from Elsevier. Reproduced from Lavie, C. J. et al. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the “obesity paradox.” J. Am. Coll. Cardiol. 60, 1374–1380 (2012), with permission from Elsevier Lavie, C. J. et al. (2017) Management of cardiovascular diseases in patients with obesity Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.108